BR112019013469A2 - Nanoconjugados de ouro com doxorrubicina direcionada para terapia de tumor - Google Patents

Nanoconjugados de ouro com doxorrubicina direcionada para terapia de tumor Download PDF

Info

Publication number
BR112019013469A2
BR112019013469A2 BR112019013469-7A BR112019013469A BR112019013469A2 BR 112019013469 A2 BR112019013469 A2 BR 112019013469A2 BR 112019013469 A BR112019013469 A BR 112019013469A BR 112019013469 A2 BR112019013469 A2 BR 112019013469A2
Authority
BR
Brazil
Prior art keywords
nanoconjugate
cancer
fact
dtdtpa
doxorubicin
Prior art date
Application number
BR112019013469-7A
Other languages
English (en)
Portuguese (pt)
Inventor
Kannan Raghuraman
Zambre Ajit
Upendran Anandhi
Original Assignee
The Curators Of The University Of Missouri
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Curators Of The University Of Missouri filed Critical The Curators Of The University Of Missouri
Publication of BR112019013469A2 publication Critical patent/BR112019013469A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/242—Gold; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y40/00—Manufacture or treatment of nanostructures

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nanotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ceramic Engineering (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
BR112019013469-7A 2017-01-09 2018-01-09 Nanoconjugados de ouro com doxorrubicina direcionada para terapia de tumor BR112019013469A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762444114P 2017-01-09 2017-01-09
US62/444,114 2017-01-09
PCT/US2018/012882 WO2018129501A1 (en) 2017-01-09 2018-01-09 Targeted doxorubicin-gold nanoconjugates for tumor therapy

Publications (1)

Publication Number Publication Date
BR112019013469A2 true BR112019013469A2 (pt) 2020-01-07

Family

ID=62791162

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019013469-7A BR112019013469A2 (pt) 2017-01-09 2018-01-09 Nanoconjugados de ouro com doxorrubicina direcionada para terapia de tumor

Country Status (12)

Country Link
US (1) US20210015944A1 (cg-RX-API-DMAC7.html)
EP (1) EP3568694B1 (cg-RX-API-DMAC7.html)
JP (1) JP7017258B2 (cg-RX-API-DMAC7.html)
KR (1) KR102568577B1 (cg-RX-API-DMAC7.html)
CN (1) CN110178028B (cg-RX-API-DMAC7.html)
AU (1) AU2018205349B2 (cg-RX-API-DMAC7.html)
BR (1) BR112019013469A2 (cg-RX-API-DMAC7.html)
CA (1) CA3048908A1 (cg-RX-API-DMAC7.html)
ES (1) ES2912286T3 (cg-RX-API-DMAC7.html)
MX (1) MX2019008233A (cg-RX-API-DMAC7.html)
WO (1) WO2018129501A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201904736B (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101887421B1 (ko) * 2016-09-20 2018-08-13 김문혜 체인 구동형 유기질비료 발효 건조장치
CN113797353B (zh) * 2020-06-12 2023-10-20 南京工业大学 一种放化疗联合治疗试剂及其制备方法
CN112494660B (zh) * 2020-12-22 2023-11-21 上海交通大学 纳米靶向药物的制备方法及在治疗胃癌中的应用
US12485484B2 (en) 2022-05-17 2025-12-02 The Government Of The United States Of America, As Represented By The Secretary Of The Navy Seedless synthesis of anisotropic gold nanoflowers with cellular control and drug delivery applications
WO2023242766A1 (en) 2022-06-15 2023-12-21 Alembic Pharmaceuticals Limited Gold nanoconjugates
CN120713846B (zh) * 2025-07-14 2026-03-31 湖南省妇幼保健院 基于铜离子和多柔比星的纳米级配位聚合物NP@DoxCu及其制备方法和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101563360A (zh) * 2006-10-20 2009-10-21 益普生制药两合公司 肽-细胞毒性缀合物
US20100021471A1 (en) * 2008-07-25 2010-01-28 Brookhaven Science Associates, Llc Carbon nanotube-based drug delivery systems and methods of making same
WO2010014812A2 (en) * 2008-07-30 2010-02-04 The Research Foundation Of State University Of New York Peptide compositions and methods of use
KR101196667B1 (ko) * 2010-04-15 2012-11-02 포항공과대학교 산학협력단 피에이치 민감성 금속 나노 입자를 이용한 항암제 전달 시스템
US9605304B2 (en) * 2011-07-20 2017-03-28 The Hong Kong Polytechnic University Ultra-stable oligonucleotide-gold and-silver nanoparticle conjugates and method of their preparation
JP6693868B2 (ja) * 2013-02-19 2020-05-13 ナショナル ヘルス リサーチ インスティテューツＮａｔｉｏｎａｌ Ｈｅａｌｔｈ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅｓ 抗癌化学療法剤用のケージ化された白金ナノクラスタ
PL3089997T3 (pl) * 2013-12-30 2020-09-07 The Curators Of The University Of Missouri Wieloskładnikowe nanomateriały au i metody syntezy

Also Published As

Publication number Publication date
RU2019125167A (ru) 2021-02-09
ES2912286T3 (es) 2022-05-25
CN110178028B (zh) 2021-04-27
ZA201904736B (en) 2021-04-28
JP7017258B2 (ja) 2022-02-08
CN110178028A (zh) 2019-08-27
KR102568577B1 (ko) 2023-08-18
US20210015944A1 (en) 2021-01-21
EP3568694B1 (en) 2022-02-16
WO2018129501A1 (en) 2018-07-12
EP3568694A4 (en) 2020-12-30
RU2019125167A3 (cg-RX-API-DMAC7.html) 2021-09-13
MX2019008233A (es) 2019-10-17
AU2018205349A1 (en) 2019-06-27
AU2018205349B2 (en) 2022-09-29
EP3568694A1 (en) 2019-11-20
JP2020504130A (ja) 2020-02-06
CA3048908A1 (en) 2018-07-12
KR20190104333A (ko) 2019-09-09

Similar Documents

Publication Publication Date Title
Qiu et al. Targeted delivery of ibrutinib to tumor-associated macrophages by sialic acid-stearic acid conjugate modified nanocomplexes for cancer immunotherapy
ES2912286T3 (es) Nanoconjugados de doxorrubicina-oro dirigido para terapia tumoral
CN103608139B (zh) 表面改性的重金属纳米粒子、组合物及其用途
Khatun et al. Oral delivery of taurocholic acid linked heparin–docetaxel conjugates for cancer therapy
Li et al. Rod-like cellulose nanocrystal/cis-aconityl-doxorubicin prodrug: a fluorescence-visible drug delivery system with enhanced cellular uptake and intracellular drug controlled release
EP3508221B1 (en) Tumor-targeting photosensitizer-drug conjugate, method for preparing same and pharmaceutical composition for preventing or treating tumor containing same
BR112019013449A2 (pt) conjugados de anticorpo fármaco (adcs) à base de inibidores de hdac e uso ms terapia
US10292940B2 (en) Hyaluronic acid-based amphiphilic polymer, preparation method and application thereof
WO2018171164A1 (zh) 一种喜树碱类前药及其制备和应用
Wang et al. Investigating the crucial roles of aliphatic tails in disulfide bond-linked docetaxel prodrug nanoassemblies
US20240009321A1 (en) Immunogenic nanovesicles for cancer immunotherapy
Ling et al. Synthesis and characterization of hyaluronic acid–platinum (iv) nanoconjugate with enhanced antitumor response and reduced adverse effects
Lee et al. Hybrid nanoparticles based on chlorin e6-conjugated hyaluronic acid/poly (l-histidine) copolymer for theranostic application to tumors
CN110167530A (zh) 基于纳米粒子的肝靶向治疗
CN107249589A (zh) 生理活性物质结合嵌段共聚物
Zhang et al. Self-assembling nanoparticles of dually hydrophobic prodrugs constructed from camptothecin analogue for cancer therapy
Ma et al. Construction of glutathione-responsive paclitaxel prodrug nanoparticles for image-guided targeted delivery and breast cancer therapy
CN112089845B (zh) 紫杉烷类药物-阿霉素前药自组装纳米粒及其应用
Xiao et al. Versatile hydrogel drug carrier loading with peptide-carbon dots conjugates for efficient targeting and synergistic suppression of breast cancer cell
KR20170031637A (ko) 고분자 또는 지질, α-리포익산 및 광감작제를 포함하는 약물전달체
Li et al. Carboxymethyl chitosan-modified folate-targeted carbon nanotubes-baicalin complexes for cancer progression and metastasis
Ma et al. Redox-responsive self-assembled podophyllotoxin twin drug nanoparticles for enhanced intracellular drug delivery
JP2019142823A (ja) 医薬組成物
Hu et al. Targeting matrix metalloproteinases activating and indoleamine 2, 3-dioxygenase suppression for triple-negative breast cancer multimodal therapy
WO2020043129A1 (zh) 含有芳硝基的连接子、含连接子的抗体偶联药物及连接子的用途

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements